Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
4 studies found for:    VX509 | Phase 2, 3
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention: Drug: VX-509
2 Completed A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo;   Drug: VX-509
3 Completed A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor
Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509;   Drug: VX-509 matching placebo
4 Active, not recruiting 24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509;   Drug: VX-509 matching placebo

Indicates status has not been verified in more than two years